Published in Front Microbiol on September 06, 2011
Titan cells in Cryptococcus neoformans: cells with a giant impact. Curr Opin Microbiol (2013) 1.02
Cryptococcus neoformans: historical curiosity to modern pathogen. Yeast (2014) 0.94
Mannoprotein MP84 mediates the adhesion of Cryptococcus neoformans to epithelial lung cells. Front Cell Infect Microbiol (2014) 0.84
Capsule growth in Cryptococcus neoformans is coordinated with cell cycle progression. MBio (2014) 0.81
Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen Shedding. Open Forum Infect Dis (2015) 0.78
Clinicopathological features of pulmonary cryptococcosis with cryptococcal titan cells: a comparative analysis of 27 cases. Int J Clin Exp Pathol (2014) 0.77
Surface architecture of fungal pathogens. Front Microbiol (2012) 0.75
Species in the Cryptococcus gattii Complex Differ in Capsule and Cell Size following Growth under Capsule-Inducing Conditions. mSphere (2016) 0.75
Neuroinvasive cryptococcosis in an immunocompetent patient with a negative spinal fluid cryptococcus antigen. Case Rep Infect Dis (2015) 0.75
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (2009) 16.37
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun (1972) 4.45
Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol (1994) 4.22
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest (1985) 3.98
Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun (1994) 3.46
The contribution of melanin to microbial pathogenesis. Cell Microbiol (2003) 3.12
Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol Immunol (1980) 2.98
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med (2007) 2.85
Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans. Cell (2008) 2.71
Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A (2002) 2.68
Expulsion of live pathogenic yeast by macrophages. Curr Biol (2006) 2.65
Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun (1987) 2.63
A yeast under cover: the capsule of Cryptococcus neoformans. Eukaryot Cell (2003) 2.59
Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell (2006) 2.55
Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect Immun (1987) 2.50
Growth of Cryptococcus neoformans within human macrophages in vitro. Infect Immun (1973) 2.39
Morphogenesis in Candida albicans. Annu Rev Microbiol (2007) 2.39
Cryptococcal cell morphology affects host cell interactions and pathogenicity. PLoS Pathog (2010) 2.28
Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun (1999) 2.22
HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis (2009) 2.18
Immunoregulation by capsular components of Cryptococcus neoformans. Med Mycol (2000) 2.14
Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network. Clin Diagn Lab Immunol (1998) 2.10
Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans. Infect Immun (1998) 2.10
Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology (2001) 2.08
The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem (2005) 2.07
Fungal cell gigantism during mammalian infection. PLoS Pathog (2010) 2.04
Regulation of cryptococcal capsular polysaccharide by iron. J Infect Dis (1993) 2.03
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect Immun (1977) 1.93
Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun (2003) 1.89
How does Cryptococcus get its coat? Trends Microbiol (2000) 1.86
CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity (2002) 1.83
Complement depletion in cryptococcal sepsis. J Immunol (1978) 1.82
Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol (2005) 1.80
Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans. J Bacteriol (1999) 1.79
Capsule synthesis by Cryptococcus neoformans. Trans N Y Acad Sci (1958) 1.76
Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. Mol Microbiol (2001) 1.74
Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun (1995) 1.70
Cryptococcus neoformans of unusual morphology. Appl Microbiol (1973) 1.67
Molecular architecture of the Cryptococcus neoformans capsule. Mol Microbiol (2004) 1.66
Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell (2007) 1.63
The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res (2006) 1.58
Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci U S A (1998) 1.58
Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect Immun (1993) 1.56
Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies. Infect Immun (1989) 1.55
Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online (2004) 1.52
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol (2003) 1.45
Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell (2007) 1.45
Dimorphism in Histoplasma capsulatum: a model for the study of cell differentiation in pathogenic fungi. Microbiol Rev (1989) 1.41
Structure determination of Cryptococcus neoformans serotype A-variant glucuronoxylomannan by 13C-n.m.r. spectroscopy. Carbohydr Res (1988) 1.41
Cryptococcus neoformans capsule biosynthesis and regulation. FEMS Yeast Res (2004) 1.39
Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryot Cell (2007) 1.39
The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol (2006) 1.37
The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin Diagn Lab Immunol (1998) 1.37
Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot Cell (2007) 1.36
The capsular dynamics of Cryptococcus neoformans. Trends Microbiol (2006) 1.35
Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect Immun (1994) 1.34
Cryptococcal titan cell formation is regulated by G-protein signaling in response to multiple stimuli. Eukaryot Cell (2011) 1.34
Cryptococcus neoformans: pseudohyphal forms surviving culture with Acanthamoeba polyphaga. Infect Immun (1978) 1.32
Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect Immun (2004) 1.31
Spatial and temporal sequence of capsule construction in Cryptococcus neoformans. Mol Microbiol (2001) 1.29
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Conversion of Blastomyces dermatitidis to the yeast form at 37 degrees C and 26 degrees C. J Clin Microbiol (1984) 1.28
Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect Immun (2003) 1.27
Glucuronoxylomannan exhibits potent immunosuppressive properties. FEMS Yeast Res (2006) 1.26
Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule. Eukaryot Cell (2006) 1.21
Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect Immun (1995) 1.21
Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. Proc Natl Acad Sci U S A (2009) 1.19
Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity. Infect Immun (2002) 1.16
The structure of Cryptococcus neoformans galactoxylomannan contains beta-D-glucuronic acid. Carbohydr Res (2009) 1.13
Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog (2011) 1.11
Profiling a killer, the development of Cryptococcus neoformans. FEMS Microbiol Rev (2011) 1.06
Rapid in vitro capsule production by cryptococci. Am J Med Technol (1979) 1.03
The volume and hydration of the Cryptococcus neoformans polysaccharide capsule. Fungal Genet Biol (2006) 1.01
Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Mol Microbiol (2011) 1.01
An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan. Res Immunol (1990) 0.97
Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo. Cell Microbiol (2010) 0.95
Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance. Cell Microbiol (2006) 0.95
Cryptococcosis in solid organ transplant recipients. Am J Transplant (2009) 0.93
Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation. Infect Immun (2010) 0.92
Type-specific polysaccharides of Cryptococcus neoformans. n.m.r.-spectral study of a glucuronomannan chemically derived from a Tremella mesenterica exopolysaccharide. Carbohydr Res (1988) 0.92
Unusual morphologies of Cryptococcus spp. in tissue specimens: report of 10 cases. Rev Inst Med Trop Sao Paulo (2010) 0.89
Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule. Mol Microbiol (2009) 0.88
Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans. Infect Immun (2006) 0.88
On the mechanism of adaptation of micro-organisms to conditions of extreme low humidity. Life Sci Space Res (1973) 0.86
Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies. J Immunol (1998) 0.86
Cryptococcal glucuronoxylomannan delays translocation of leukocytes across the blood-brain barrier in an animal model of acute bacterial meningitis. J Neuroimmunol (2000) 0.86
Immunoreactivity of cryptococcal antigen is not stable under prolonged incubations in human serum. J Clin Microbiol (2004) 0.85
Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence (2010) 0.84
Atypical cytomorphologic appearance of Cryptococcus neoformans: a report of five cases. Acta Cytol (1996) 0.84
Fungi and molds following lung transplantation. Semin Respir Crit Care Med (2010) 0.83
Cryptococcal glucuronoxylomannan inhibits adhesion of neutrophils to stimulated endothelium in vitro by affecting both neutrophils and endothelial cells. Infect Immun (2002) 0.80
Polarization optical analysis of the surface structures of various fungi. Acta Histochem (2009) 0.76